What’s happening: A bipartisan group of U.S. representatives is leading a letter to U.S. Health and Human Services (HHS) Secretary Xavier Becerra about efforts by Johnson & Johnson (J&J) to undermine the 340B Drug Discount Program.
What else to know: Hospital leaders should call or email their U.S. representative and urge them to sign on to the letter by Sept. 27.
The letter expresses concern about J&J’s efforts to transition two 340B drugs, Stelara and Xarelto, from direct discounts to a rebate model for disproportionate share hospitals. The letter urges the department to prevent this model from taking effect.
Last week, the Health Resources & Services Administration (HRSA) sent a letter to J&J warning that their rebate proposal violates obligations under the 340B statute and that J&J should cease implementation immediately. CHA sent a letter to HHS Sec. Becerra and HRSA Administrator Carole Johnson in support of HRSA’s position.
Find your representative’s contact information on CHA’s Federal Legislative Tracker by clicking on the representative’s photograph.
- House Democrats should email Lucy Schwartz (lucy.schwartz@mail.house.gov) in Rep. Spanberger’s (D-VA) office.
- House Republicans should email Sydney Powers (sydney.powers@mail.house.gov) in Rep. Johnson’s (R-SD) office.
The letter currently has 151 signatures, including 26 members of the California congressional delegation:
- Bera (D-CA-6)
- Brownley (D-CA-26)
- Carbajal (D-CA-24)
- Cárdenas (D-CA-29)
- Chu (D-CA-28)
- Costa (D-CA-21)
- DeSaulnier (D-CA-10)
- Eshoo (D-CA-16)
- Fong (R-CA-20)
- Garamendi (D-CA-8)
- Garcia, Mike (R-CA-27)
- Garcia, Robert (D-CA-42)
- Gomez, Jimmy (D-CA-34)
- Harder (D-CA-9)
- Kamlager-Dove (D-CA-37)
- Khanna (D-CA-17)
- Lee (D-CA-12)
- Lieu (D-CA-36)
- Lofgren (D-CA-18)
- Matsui (D-CA-7), lead author
- Panetta (D-CA-19)
- Schiff (D-CA-30)
- Thompson (D-CA-4)
- Valadao (R-CA-22)
- Vargas (D-CA-52)
- Waters (D-CA-43)
